West Cancer Center

ADVANCED SOLID TUMORS: PHASE 1: LAST LINE: SLITRK6 ADC: GEN1106

First-In-Human, Open-Label, Dose Escalation and Expansion Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of GEN1106 in Participants With Solid Tumors

Title

Genmab GCT1106-01 Phase 1

Study Title

First-In-Human, Open-Label, Dose Escalation and Expansion Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of GEN1106 in Participants With Solid Tumors

Site Link

NCT07416123

Malignancy

Bone, Breast, Bladder, Colon, Prostate, Melanoma, RCC, Kidney, Rectal, Lung, NSCLC, SCLC, Soft Tissue, Ovarian, Endometrial, Cervical

Stage

Stage 4

Disease Setting

Metastatic/Palliative

Line Of Therapy

Last Line

Investigational Agent

GEN1106

Drug Class

SLITRK6 ADC

Dan Vaena, MD

Sponsor

Genmab

Phase

Phase 1

Status

Open to Enrollment

Key Eligibility Criteria

Key Eligibility Criteria Details

Have received and progressed on, been ontolerant to, or be inelgibile for all available SOC therapies known to provide a survival or QOL benefit for the specific tumor type
Measurable disease
ECOG PS 0-1
No prior treatment with topo-1 inhibitor based ADC

Objective

Primary
- DLT
- Safety
Secondary
- ORR
- PK
- DCR
- DOR
- TTR

Assessment Frequency

Assessment Frequency 2

Assessment Frequency Link

Path

Any

Dosing Frequency

Control Agents

Study Protocol

Randomized